Texas Court Won't Revive $10M Award Against Fen-Phen Atty

Law360, Houston (April 9, 2013, 3:55 PM EDT) -- A Texas appeals court on Tuesday ruled for a second time that faulty testimony underpinned a jury’s verdict that resulted in awards exceeding $10 million against a Houston attorney who allegedly overcharged clients in litigation against a Pfizer Inc. unit over the diet drug fen-phen.

The Fourteenth District Court of Appeals denied a request by a 600-member client group to reconsider its February decision that testimony of a legal ethics expert in a test case against attorney George Fleming “crossed the border of admissibility."

Lillian Hardwick...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.